Earnings digests and industry comparisons for Japan's biggest listed companies.
5 reports
Olympus said the FDA issued an import alert for some products made at three group facilities in Japan, restricting U.S. imports until further notice. It sees no additional impact on fiscal 2027 results and kept its forecast unchanged.
Olympus received a Warning Letter from the US FDA regarding quality management at six facilities. The company stated the disclosure has no impact on consolidated financial results, reassuring investors of operational stability.
Medical equipment giant Terumo will recognize a massive loss of approximately $610 million due to the termination of a key supply contract. Consequently, the company has revised its full-year operating profit forecast downward by roughly 38 percent.
Sysmex announced the cancellation of 21.14 million treasury shares as of Sept. 30, reducing total issued shares by roughly 3.4 pct. This move aims to strengthen capital efficiency and is expected to lift earnings per share.
Japan Activation Capital's funds have acquired 10.41 million shares of Nihon Kohden, expanding its voting rights stake to 6.48 percent. This transaction marks a significant shift in the company's major shareholder structure.
